Vaxart reports improved antibody response in norovirus vaccine trial

Vaxart (VXRT) announced positive Phase 1 clinical trial results for its second-generation oral norovirus vaccine candidates, demonstrating statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies compared to first-generation constructs; the company plans to leverage these results in discussions with potential partners for a Phase 2b study potentially beginning in the second half of 2025. The company is also seeking shareholder approval for a reverse stock split to meet Nasdaq requirements and expanding its Phase 2b COVID-19 vaccine trial with potential funding up to $460.7 million from Project NextGen, while implementing cost reductions to extend its cash runway into 2026.

Analysis

Vaxart, Inc. (VXRT) reported encouraging Phase 1 clinical trial results for its second-generation oral norovirus vaccine candidates, demonstrating a statistically significant 141% increase in GI.1 and a 94% increase in GII.4 norovirus blocking antibodies compared to its first-generation constructs at the higher dose level. These candidates were deemed safe and well-tolerated. This development is notable given the absence of an approved norovirus vaccine and the substantial global health impact, with approximately 685 million annual infections and a $60 billion economic burden. The company, with a market capitalization around $90 million and shares down nearly 49% over the past year, plans to leverage these positive results in discussions with potential partners to fund a Phase 2b study, potentially commencing in the second half of 2025. Despite ongoing development costs, InvestingPro analysis indicates a favorable cash-to-debt position and a "FAIR" financial health score. Concurrently, Vaxart is addressing its Nasdaq listing requirements by seeking shareholder approval for a reverse stock split, a proposal supported by proxy advisory firms. The company is also advancing its COVID-19 vaccine program, with U.S. government approval to expand its Phase 2b trial to 10,000 participants, potentially securing_up to $460.7 million in funding from Project NextGen. Strategic cost reductions, including workforce cuts, and the appointment of a new CFO, Jeroen Grasman, aim to extend Vaxart's cash runway into 2026, supporting its focus on its oral recombinant vaccine platform.

Key Decisions for Investors

• Investors should consider the positive Phase 1 norovirus data as a key milestone, but recognize that securing partnerships or additional funding is critical for advancing to the more expensive Phase 2b trial.
• Monitor Vaxart's progress in obtaining non-dilutive funding, particularly the materialization of the potential $460.7 million from Project NextGen for its COVID-19 vaccine, as this could significantly impact its financial runway and development capabilities.
• Evaluate the implications of the proposed reverse stock split in the context of maintaining Nasdaq compliance versus the company's ability to execute on its clinical pipeline and secure necessary capital, noting the extended cash runway to 2026 against ongoing R&D investment.